CN111840280A - Children eczema ointment and preparation method thereof - Google Patents
Children eczema ointment and preparation method thereof Download PDFInfo
- Publication number
- CN111840280A CN111840280A CN202010671598.2A CN202010671598A CN111840280A CN 111840280 A CN111840280 A CN 111840280A CN 202010671598 A CN202010671598 A CN 202010671598A CN 111840280 A CN111840280 A CN 111840280A
- Authority
- CN
- China
- Prior art keywords
- parts
- ointment
- borneol
- eczema
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Abstract
The invention discloses a children eczema ointment and a preparation method thereof, and belongs to the field of eczema medicines. The miconazole nitrate can inhibit the synthesis of fungal cell membranes and kill fungi, all the medicinal components are matched with each other, so that the ointment for treating the eczema provided by the invention has the effects of relieving itching, diminishing inflammation, inhibiting bacteria and killing bacteria, particularly has obvious effects on fungal infection and eczema infection, is safe and non-irritant to use, and is suitable for external administration of children.
Description
Technical Field
The invention belongs to the field of eczema medicaments, and particularly relates to a children eczema ointment and a preparation method thereof.
Background
Eczema is a superficial dermal and epidermal inflammation caused by various internal and external factors, and the cause of the disease is complex. The existing eczema treatment method is generally an external medicament and an internal medicament, but the intestines and stomach of children are weak and are not suitable for the internal medicament, and the existing external medicament has great irritation to the skin, so that the skin allergy and even the injury of the children are easily caused.
Disclosure of Invention
The invention provides an ointment for treating children eczema, and provides an external medicament suitable for treating children eczema.
The invention is realized by the following technical scheme.
The children eczema ointment is prepared from the following raw materials in parts by weight:
2-5 parts of hexadecanol, 1-6 parts of octadecanol, 1-2 parts of oleic acid, 2-5 parts of fatty acid monoglyceride, 1-2 parts of paraffin, 3-6 parts of glycerol, 1-2 parts of propylene glycol, 4-7 parts of borneol, 1-2 parts of miconazole nitrate, 0.1-0.3 part of azone, 0.1-0.3 part of dimethyl sulfoxide, 0.1-0.3 part of fatty alcohol polyoxyethylene ether, 0.1-0.3 part of tween-20, 0.1-0.3 part of methylparaben and 70-80 parts of water.
In a specific embodiment, 2 parts of cetyl alcohol, 1 part of stearyl alcohol, 1 part of oleic acid, 2 parts of fatty acid monoglyceride, 1 part of paraffin, 3 parts of glycerol, 1 part of propylene glycol, 4 parts of borneol, 1 part of miconazole nitrate, 0.1 part of azone, 0.1 part of dimethyl sulfoxide, 0.1 part of fatty alcohol-polyoxyethylene ether, 0.1 part of tween-20, 0.1 part of methylparaben and 70 parts of water.
In a specific embodiment, 5 parts of hexadecanol, 6 parts of octadecanol, 2 parts of oleic acid, 5 parts of fatty acid monoglyceride, 2 parts of paraffin, 6 parts of glycerol, 2 parts of propylene glycol, 7 parts of borneol, 2 parts of miconazole nitrate, 0.3 part of azone, 0.3 part of dimethyl sulfoxide, 0.3 part of fatty alcohol-polyoxyethylene ether, 0.3 part of tween-20, 0.3 part of methyl paraben and 80 parts of water.
In a specific embodiment, 3 parts of hexadecanol, 2 parts of octadecanol, 1 part of oleic acid, 3 parts of fatty acid monoglyceride, 1 part of paraffin, 4 parts of glycerol, 1 part of propylene glycol, 5 parts of borneol, 1 part of miconazole nitrate, 0.2 part of azone, 0.1 part of dimethyl sulfoxide, 0.1 part of fatty alcohol-polyoxyethylene ether, 0.2 part of tween-20, 0.1 part of methylparaben and 75 parts of water.
In a specific embodiment, 4 parts of hexadecanol, 3 parts of octadecanol, 2 parts of oleic acid, 4 parts of fatty acid monoglyceride, 2 parts of paraffin, 5 parts of glycerol, 2 parts of propylene glycol, 6 parts of borneol, 2 parts of miconazole nitrate, 0.3 part of azone, 0.2 part of dimethyl sulfoxide, 0.2 part of fatty alcohol-polyoxyethylene ether, 0.3 part of tween-20, 0.2 part of methylparaben and 76 parts of water.
In a specific embodiment, the ointment for treating children eczema further comprises an auxiliary material, wherein the auxiliary material is prepared from the following raw materials in parts by weight
5-6 parts of borneol, 44-45 parts of talcum powder, 23-24 parts of zinc oxide and 26-27 parts of calcium carbonate.
In a specific embodiment, the composition comprises 5 parts of borneol, 44 parts of talcum powder, 23 parts of zinc oxide and 26 parts of calcium carbonate.
In a specific embodiment, 6 parts of borneol, 45 parts of talcum powder, 24 parts of zinc oxide and 27 parts of calcium carbonate.
The application also provides a preparation method of the children eczema ointment, which comprises the following steps:
Mixing and heating hexadecanol, octadecanol, propylene glycol, dimethyl sulfoxide and fatty alcohol-polyoxyethylene ether with water to obtain a water phase mixture;
mixing oleic acid, fatty acid monoglyceride, glycerol, paraffin, azone, tween-20, and methyl hydroxybenzoate, and heating to obtain oil phase mixture;
grinding borneol and mixing the ground borneol and miconazole nitrate to obtain an additive, and heating to 30-40 ℃;
mixing and stirring the water phase mixture and the oil phase mixture, reducing the temperature to 30-40 ℃ in the stirring process, and continuously stirring for 5min to obtain a paste;
and pouring the additives into the paste, continuously stirring for 10-15 min, cooling, and subpackaging.
The invention has the beneficial effects that:
the miconazole nitrate can inhibit the synthesis of fungal cell membranes and kill fungi, all the medicinal components are matched with each other, so that the ointment for treating the eczema provided by the invention has the effects of relieving itching, diminishing inflammation, inhibiting bacteria and killing bacteria, particularly has obvious effects on fungal infection and eczema infection, is safe and non-irritant to use, and is suitable for external administration of children.
Detailed Description
The technical solution of the present invention is further described below, but the scope of the claimed invention is not limited to the described.
The invention provides an ointment for treating children eczema, which is prepared from the following raw materials in parts by weight:
2-5 parts of hexadecanol, 1-6 parts of octadecanol, 1-2 parts of oleic acid, 2-5 parts of fatty acid monoglyceride, 1-2 parts of paraffin, 3-6 parts of glycerol, 1-2 parts of propylene glycol, 4-7 parts of borneol, 1-2 parts of miconazole nitrate, 0.1-0.3 part of azone, 0.1-0.3 part of dimethyl sulfoxide, 0.1-0.3 part of fatty alcohol polyoxyethylene ether, 0.1-0.3 part of tween-20, 0.1-0.3 part of methylparaben and 70-80 parts of water.
The invention provides a preparation method of an ointment for treating children eczema, which comprises the following steps:
mixing and heating hexadecanol, octadecanol, propylene glycol, dimethyl sulfoxide and fatty alcohol-polyoxyethylene ether with water to obtain a water phase mixture;
mixing oleic acid, fatty acid monoglyceride, glycerol, paraffin, azone, tween-20, and methyl hydroxybenzoate, and heating to obtain oil phase mixture;
grinding borneol and mixing the ground borneol and miconazole nitrate to obtain an additive, and heating to 30-40 ℃;
mixing and stirring the water phase mixture and the oil phase mixture, reducing the temperature to 30-40 ℃ in the stirring process, and continuously stirring for 5min to obtain a paste;
and pouring the additives into the paste, continuously stirring for 10-15 min, cooling, and subpackaging.
The first embodiment is as follows:
2 parts of hexadecanol, 1 part of octadecanol, 1 part of oleic acid, 2 parts of fatty acid monoglyceride, 1 part of paraffin, 3 parts of glycerol, 1 part of propylene glycol, 4 parts of borneol, 1 part of miconazole nitrate, 0.1 part of azone, 0.1 part of dimethyl sulfoxide, 0.1 part of fatty alcohol-polyoxyethylene ether, 0.1 part of tween-20, 0.1 part of methylparaben and 70 parts of water.
Example two:
5 parts of hexadecanol, 6 parts of octadecanol, 2 parts of oleic acid, 5 parts of fatty acid monoglyceride, 2 parts of paraffin, 6 parts of glycerol, 2 parts of propylene glycol, 7 parts of borneol, 2 parts of miconazole nitrate, 0.3 part of azone, 0.3 part of dimethyl sulfoxide, 0.3 part of fatty alcohol-polyoxyethylene ether, 0.3 part of tween-20, 0.3 part of methylparaben and 80 parts of water.
Example three:
3 parts of hexadecanol, 2 parts of octadecanol, 1 part of oleic acid, 3 parts of fatty acid monoglyceride, 1 part of paraffin, 4 parts of glycerol, 1 part of propylene glycol, 5 parts of borneol, 1 part of miconazole nitrate, 0.2 part of azone, 0.1 part of dimethyl sulfoxide, 0.1 part of fatty alcohol-polyoxyethylene ether, 0.2 part of tween-20, 0.1 part of methylparaben and 75 parts of water.
Example four:
4 parts of hexadecanol, 3 parts of octadecanol, 2 parts of oleic acid, 4 parts of fatty acid monoglyceride, 2 parts of paraffin, 5 parts of glycerol, 2 parts of propylene glycol, 6 parts of borneol, 2 parts of miconazole nitrate, 0.3 part of azone, 0.2 part of dimethyl sulfoxide, 0.2 part of fatty alcohol-polyoxyethylene ether, 0.3 part of tween-20, 0.2 part of methylparaben and 76 parts of water.
Counting time: the patient is required to be 0-12 years old from 30 months 6 in 2019 to 29 months 6 in 2020.
Clinical data: 259 cases of eczema patients, wherein 158 cases of boys are aged 2-12 years, 101 cases of girls are aged 1-12 years.
The treatment method comprises the following steps: firstly, cleaning the affected part, then externally applying the plaster to the affected part, and then using auxiliary materials, wherein the auxiliary materials are prepared from the following raw materials in parts by weight: 5-6 parts of borneol, 44-45 parts of talcum powder, 23-24 parts of zinc oxide and 26-27 parts of calcium carbonate. For example, 5 parts of borneol, 44 parts of talcum powder, 23 parts of zinc oxide and 26 parts of calcium carbonate. 6 parts of borneol, 45 parts of talcum powder, 24 parts of zinc oxide and 27 parts of calcium carbonate.
The medicine is taken in the morning and at night every day, and a treatment course is taken every three days.
The treatment results are as follows: 255 cases are cured, the affected part is obviously improved after two treatment courses, 4 treatment courses are basically cured, and the skin of the children does not have any discomfort. The effective rate reaches 98.45 percent after 5 cases of invalidity.
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and it is not intended that the invention be limited to these specific details. For those skilled in the art to which the invention pertains, several equivalent substitutions or obvious modifications can be made without departing from the spirit of the invention, and all the same properties or uses should be considered as belonging to the invention.
Claims (9)
1. The children eczema ointment is characterized in that: is prepared from the following raw materials in part by weight
2-5 parts of hexadecanol, 1-6 parts of octadecanol, 1-2 parts of oleic acid, 2-5 parts of fatty acid monoglyceride, 1-2 parts of paraffin, 3-6 parts of glycerol, 1-2 parts of propylene glycol, 4-7 parts of borneol, 1-2 parts of miconazole nitrate, 0.1-0.3 part of azone, 0.1-0.3 part of dimethyl sulfoxide, 0.1-0.3 part of fatty alcohol polyoxyethylene ether, 0.1-0.3 part of tween-20, 0.1-0.3 part of methylparaben and 70-80 parts of water.
2. The ointment for treating children eczema as claimed in claim 1, wherein the ointment comprises 2 parts of cetyl alcohol, 1 part of stearyl alcohol, 1 part of oleic acid, 2 parts of fatty acid monoglyceride, 1 part of paraffin, 3 parts of glycerol, 1 part of propylene glycol, 4 parts of borneol, 1 part of miconazole nitrate, 0.1 part of azone, 0.1 part of dimethyl sulfoxide, 0.1 part of fatty alcohol-polyoxyethylene ether, 0.1 part of tween-20, 0.1 part of methylparaben and 70 parts of water.
3. The ointment for treating children eczema as claimed in claim 1, wherein the ointment comprises 5 parts of cetyl alcohol, 6 parts of stearyl alcohol, 2 parts of oleic acid, 5 parts of fatty acid monoglyceride, 2 parts of paraffin, 6 parts of glycerol, 2 parts of propylene glycol, 7 parts of borneol, 2 parts of miconazole nitrate, 0.3 part of azone, 0.3 part of dimethyl sulfoxide, 0.3 part of fatty alcohol-polyoxyethylene ether, 0.3 part of tween-20, 0.3 part of methylparaben and 80 parts of water.
4. The ointment for treating children eczema as claimed in claim 1, wherein the ointment comprises 3 parts of cetyl alcohol, 2 parts of stearyl alcohol, 1 part of oleic acid, 3 parts of fatty acid monoglyceride, 1 part of paraffin, 4 parts of glycerol, 1 part of propylene glycol, 5 parts of borneol, 1 part of miconazole nitrate, 0.2 part of azone, 0.1 part of dimethyl sulfoxide, 0.1 part of fatty alcohol-polyoxyethylene ether, 0.2 part of tween-20, 0.1 part of methylparaben and 75 parts of water.
5. The ointment for treating children eczema as claimed in claim 1, wherein the ointment comprises 4 parts of cetyl alcohol, 3 parts of stearyl alcohol, 2 parts of oleic acid, 4 parts of fatty acid monoglyceride, 2 parts of paraffin, 5 parts of glycerol, 2 parts of propylene glycol, 6 parts of borneol, 2 parts of miconazole nitrate, 0.3 part of azone, 0.2 part of dimethyl sulfoxide, 0.2 part of fatty alcohol-polyoxyethylene ether, 0.3 part of tween-20, 0.2 part of methylparaben and 76 parts of water.
6. The ointment for treating children eczema as claimed in claim 1, further comprising an auxiliary material, wherein the auxiliary material is prepared from the following raw materials in parts by weight
5-6 parts of borneol, 44-45 parts of talcum powder, 23-24 parts of zinc oxide and 26-27 parts of calcium carbonate.
7. The ointment for treating children eczema as claimed in claim 6, wherein the ointment comprises 5 parts of borneol, 44 parts of talcum powder, 23 parts of zinc oxide and 26 parts of calcium carbonate.
8. The ointment for treating children eczema as claimed in claim 6, wherein the ointment comprises 6 parts of borneol, 45 parts of talcum powder, 24 parts of zinc oxide and 27 parts of calcium carbonate.
9. A method for preparing an ointment for eczema of children as claimed in any one of claims 1 to 8, which comprises the steps of:
mixing and heating hexadecanol, octadecanol, propylene glycol, dimethyl sulfoxide and fatty alcohol-polyoxyethylene ether with water to obtain a water phase mixture;
Mixing oleic acid, fatty acid monoglyceride, glycerol, paraffin, azone, tween-20, and methyl hydroxybenzoate, and heating to obtain oil phase mixture;
grinding borneol and mixing the ground borneol and miconazole nitrate to obtain an additive, and heating to 30-40 ℃;
mixing and stirring the water phase mixture and the oil phase mixture, reducing the temperature to 30-40 ℃ in the stirring process, and continuously stirring for 5min to obtain a paste;
and pouring the additives into the paste, continuously stirring for 10-15 min, cooling, and subpackaging.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010671598.2A CN111840280A (en) | 2020-07-14 | 2020-07-14 | Children eczema ointment and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010671598.2A CN111840280A (en) | 2020-07-14 | 2020-07-14 | Children eczema ointment and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111840280A true CN111840280A (en) | 2020-10-30 |
Family
ID=72983337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010671598.2A Pending CN111840280A (en) | 2020-07-14 | 2020-07-14 | Children eczema ointment and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111840280A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1346634A (en) * | 2001-07-23 | 2002-05-01 | 广东庆发药业有限公司 | Process for preparing miconazole nitrate ointment |
| CN101890045A (en) * | 2009-05-23 | 2010-11-24 | 李文琳 | External medicament for treating infantile eczema |
| US20140057859A1 (en) * | 2007-01-30 | 2014-02-27 | Cypress Pharmaceuticals, Inc. | Hyaluronate Compositions |
| CN104825460A (en) * | 2015-03-30 | 2015-08-12 | 上海中华药业南通有限公司 | Dermatomycosis treatment emulsifiable paste and preparation method thereof |
| CN109820860A (en) * | 2019-04-19 | 2019-05-31 | 江苏远恒药业有限公司 | A kind of Compound Miconazole nitrate Cream and its preparation process |
-
2020
- 2020-07-14 CN CN202010671598.2A patent/CN111840280A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1346634A (en) * | 2001-07-23 | 2002-05-01 | 广东庆发药业有限公司 | Process for preparing miconazole nitrate ointment |
| US20140057859A1 (en) * | 2007-01-30 | 2014-02-27 | Cypress Pharmaceuticals, Inc. | Hyaluronate Compositions |
| US20150320788A1 (en) * | 2007-01-30 | 2015-11-12 | Cypress Pharmaceuticals, Inc. | Hyaluronate Compositions |
| CN101890045A (en) * | 2009-05-23 | 2010-11-24 | 李文琳 | External medicament for treating infantile eczema |
| CN104825460A (en) * | 2015-03-30 | 2015-08-12 | 上海中华药业南通有限公司 | Dermatomycosis treatment emulsifiable paste and preparation method thereof |
| CN109820860A (en) * | 2019-04-19 | 2019-05-31 | 江苏远恒药业有限公司 | A kind of Compound Miconazole nitrate Cream and its preparation process |
Non-Patent Citations (5)
| Title |
|---|
| 何昌善: "《临症用药纲目》", 31 August 2017, 中国医药科技出版社 * |
| 侯海云等: "《表面活性剂物理化学基础》", 31 August 2014, 西安交通大学出版社 * |
| 张兆旺: "《中药药剂学 供中药类专业用 新世纪 第2版》", 31 July 2017, 中国中医药出版社 * |
| 胡功政等: "《新全实用兽药手册》", 30 September 2009, 河南科学技术出版社 * |
| 董文燊等: "促透皮吸收剂对菌克软膏中硝酸咪康唑透皮吸收的影响", 《实用药物与临床》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109044915B (en) | Infant hip-protecting cream and preparation process thereof | |
| KR101135172B1 (en) | A composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Phellodendron amurense Rupr, Houttuynia cordata, Paeonia lactiflora Pall, Agrimonia pilosa Ledeb, and Glycyrrhiza uralensis Fisch as an effective ingredient | |
| CN102641299A (en) | Externally-applied medicament composite for treating hemorrhoids | |
| CN108704021B (en) | Composition for skin allergy and skin barrier damage and preparation method thereof | |
| EA029649B1 (en) | Pomegranate-peel polyphenol gel used to treat gynecological inflammation diseases and method for preparation thereof | |
| WO2022178983A1 (en) | External preparation of natural drug, preparation method, and application thereof | |
| US8124133B2 (en) | Use of the total coumarins of Cnidium monnieri in preparation of the medicament for treating psoriasis | |
| KR100894439B1 (en) | The composition for cosmetics having the prevention effect of atopy | |
| CN114099604A (en) | Biological dressing with scar preventing function and preparation method thereof | |
| CN112972484A (en) | Application of trilobatin in preparation of medicine for promoting skin wound healing | |
| KR101840646B1 (en) | Cosmetic composition comprising extract of Lotus corniculatus for improving acne | |
| CN111840280A (en) | Children eczema ointment and preparation method thereof | |
| CN110897904A (en) | Skin membrane repairing cream and preparation process thereof | |
| CN113925907B (en) | Antibacterial, anti-inflammatory and antiallergic composition, and preparation method and application thereof | |
| CN114452297B (en) | Medicinal preparation for treating dermatitis and preparation method thereof | |
| CN102872158B (en) | External drug combination for curing eczema and preparation method thereof | |
| KR20160083299A (en) | Ointment composition of the aerial part of Glechoma grandis Kuprianova var. longituba Kitagawa on scalded wound healing | |
| US11154583B2 (en) | Composition and method of skin relief cream useful for eczema, psoriasis, lipoma, burn wounds, scars, keloids, shingles, dry skin disorders, and skin allergies | |
| CN110051719B (en) | Mixed extract of garden balsam stem and Chinese arborvitae twig and extraction process and application thereof | |
| KR100202058B1 (en) | Mixed whitening compositions | |
| JP2860550B2 (en) | Acute skin inflammation treatment | |
| CN112245483A (en) | Formula of paste dressing for treating rhagadia manus et pedis and preparation method thereof | |
| CN104546880A (en) | External preparation for treating facial seborrheic dermatitis | |
| CN109432290B (en) | Traditional Chinese medicine composition with skin anti-allergy effect and aqueous extract and fermentation product and application thereof | |
| CN102440946A (en) | Preparation method of dyclonine ointment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201030 |
|
| WD01 | Invention patent application deemed withdrawn after publication |